Navigation Links
Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
Date:9/8/2009

EAST BRUNSWICK, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that five abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009. The posters will be presented during the "Treatment and Outcome" session on October 19, 2009 and include:

  • Chronic Use of Pegloticase: Safety and Efficacy Update (Abstract # 1113) - October 19, 2009 at 9:00 a.m. Eastern Time

  • First Application of Computer-Assisted Analysis of Digital Photographs for Assessing Tophus Response: Phase 3 Studies of Pegloticase in Treatment Failure Gout (Abstract # 1111) - October 19, 2009 at 9:00 a.m. Eastern Time

  • Improvement in Health-Related Quality of Life (HRQOL) in Patients with Treatment Failure Gout (TFG) Treated with Pegloticase Measured by SF-6D Derived Utility (Abstract # 1101) - October 19, 2009 at 9:00 a.m. Eastern Time

  • Routine Serum Uric Acid (SUA) Monitoring Predicts Antibody-Mediated Loss of Response and Infusion Reaction Risk during Pegloticase Therapy (Abstract # 1104) - October 19, 2009 at 9:00 a.m. Eastern Time

  • The Costs of Treatment Failure Gout: A Claims-Based Analysis (Abstract # 1112) - October 19, 2009 at 9:00 a.m. Eastern Time

For complete information on all five abstracts, please visit the American College of Rheumatology website at www.rheumatology.org.

ABOUT SAVIENT PHARMACEUTI
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
2. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
3. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections
6. MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air
7. iCardiac Selected for Multiple Cardiac Safety Studies
8. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
9. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
10. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
11. Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a ... new 41,500 ft2 facility. The planned move will double ... W. 116th St. in Lenexa, KS. The new facility, ... space, will remain in the Kansas City metro area, just ... twenty years ago. Remaining in the Kansas City area ...
(Date:4/21/2015)... April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... multi-arm Phase 1 study of MM-141, a bispecific antibody ... an oral session by Dr. Mansoor Saleh , ... Annual Meeting in Philadelphia, PA. ... as a monotherapy and in combination with everolimus or ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
(Date:4/21/2015)... April 21, 2015 PRC Clinical, ... and exhibit at the ACRP 2015 Global Conference and ... Utah. The Association of Clinical Research Professionals (ACRP) Global ... conference solely focused on the conduct of clinical trials. ... development, and widely recognized industry certifications. , The ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... Pharma, Inc., a privately-,held, specialty pharmaceutical company, announced ... A financing, which included investors Domain Associates,Latterell Venture ... is committed to the development of prescription,products based ... the unmet,needs of patients and their caregivers. Meritage ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Annual Growth Stock on Wednesday, June 18, 2008 at,approximately ... be,webcast live and may be accessed through a link ... http://www.gen-probe.com . The webcast will be,available for 30 days ...
... - Potential to combine compounds with multiple new and existing ... with activity ... against drug-resistant organisms -, SAN DIEGO and LONDON, June ... have entered into a,worldwide strategic alliance for the discovery, development ...
Cached Biology Technology:Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing 2Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Extra genomes appear, on average, to offer no benefit or ... the origin of new species, say scientists from Indiana University ... of the National Academy of Sciences . Plant biologists ... chromosome sets -- was a gateway to speciation. But the ...
... Folsom, CA August 11, 2009 On Monday, August ... 90th Annual Pacific Division Meeting of the AAAS in San ... science communication from some of the brightest minds in the ... Part of the Job: Communicating Science to the Public. (Online ...
... at Oregon State University have discovered that the circadian rhythms ... more susceptible to pesticides at some times of the day ... it may be possible to tap into this genetic characteristic, ... to a specific pesticide, and use that information to increase ...
Cached Biology News:Genome duplication responsible for more plant species than previously thought 2Genome duplication responsible for more plant species than previously thought 3Science communication to take the stage at annual AAAS meeting in San Francisco 2Biological clocks of insects could lead to more effective pest control 2Biological clocks of insects could lead to more effective pest control 3
Luminometers...
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
Biology Products: